(Q36800624)

16 August 2017

1 reference

title

The role of vildagliptin in the management of type 2 diabetes mellitus (English)

1 reference

16 August 2017

1 reference

Erika L Kleppinger

1

1 reference

PubMed ID

17456545

16 August 2017

Kristen Helms

series ordinal

2

1 reference

PubMed ID

17456545

16 August 2017

language of work or name

English

0 references

publication date

24 April 2007

1 reference

Annals of Pharmacotherapy

16 August 2017

1 reference

16 August 2017

41

1 reference

16 August 2017

5

1 reference

16 August 2017

824-832

1 reference

Pharmacologic therapy for type 2 diabetes mellitus

16 August 2017

1 reference

Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

Standards of medical care in diabetes--2007.

21 January 2018

1 reference

Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents?

21 January 2018

1 reference

Glucagon-like peptide 1 and gastric inhibitory polypeptide: potential applications in type 2 diabetes mellitus

21 January 2018

1 reference

Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes

21 January 2018

1 reference

Gut-derived incretin hormones and new therapeutic approaches

21 January 2018

1 reference

Dipeptidyl peptidase IV inhibitors for the treatment of diabetes

21 January 2018

1 reference

1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties

21 January 2018

1 reference

Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes

21 January 2018

1 reference

Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by Vildagliptin ((2S)-{[(3-hydroxyadamantan-1-yl)amino]acetyl}-pyrrolidine-2-carbonitrile).

21 January 2018

1 reference

Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response

21 January 2018

1 reference

Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes.

21 January 2018

1 reference

Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial.

21 January 2018

1 reference

Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

21 January 2018

1 reference

Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year

21 January 2018

1 reference

Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1H460

1 reference

16 August 2017

1 reference

PubMed ID

17456545